E
LSL Pharma Group Inc. LSL.V
TSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

09/30/2024 06/30/2024 03/31/2024 12/31/2023 09/30/2023
Net Income 50.18% 51.15% 94.80% 84.26% 49.48%
Total Depreciation and Amortization 0.31% 17.57% 34.55% -17.88% 35.37%
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items 8.48% 95.82% -87.42% -154.73% 21.72%
Change in Net Operating Assets 78.79% -290.25% 23.34% -265.48% -1,113.60%
Cash from Operations 96.47% -1,267.16% 58.92% 59.51% -267.47%
Capital Expenditure -532.23% -296.55% -361.93% 85.85% 1.98%
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities -558.06% -1,905.41% -485.41% 22.82% --
Cash from Investing -549.27% -1,223.78% -383.44% 222.23% -11.17%
Total Debt Issued -40.27% -47.54% 214.50% -97.22% 969.92%
Total Debt Repaid -480.00% -229.94% 84.63% 1,525.61% 68.51%
Issuance of Common Stock -- -- -79.02% -- --
Repurchase of Common Stock -- -- -- 99.97% --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities 40.74% -84.82% 83.07% -23.52% -197.20%
Cash from Financing -36.33% -- -53.80% -83.56% 183.25%
Foreign Exchange rate Adjustments -- -- -- -- --
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash 77.46% 236.80% -105.51% 144.17% -389.52%
Weiss Ratings